Confocal and Multiphoton Microscopy Patents: Leaders & Trends 2026
- Concentrated but not locked up. the ranked leader holds 485 records yet the top 5 combined account for only 13.2% of all 11,824 records in scope — no single entity controls the field.
- Filing has cooled from its 2018 peak. activity ran 631 records in 2021 down to 314 in 2024, a -50% swing over that span, with the drop concentrated after the pandemic-era filing surge.
- Chemistry and biology classes outweigh optics. A61K (medicinal preparations) and G01N (material analysis) each cover roughly 30% of records, ahead of G02B optical systems at 17.3% — most filings frame the microscope as a diagnostic or therapeutic tool, not a standalone instrument.
Filing growth compares 2021 (631 records) with 2024 (314) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 11,824 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Confocal and multiphoton microscopy patenting spans two very different filing traditions. One line of records treats the microscope as an optical instrument — pinhole geometry, scanning speed, spectral detection — and files under G02B. A larger line treats it as a diagnostic or research tool bundled with an assay, a probe chemistry or a therapeutic claim, filing instead under A61K, G01N or C12N. That split matters for freedom-to-operate work: a search limited to optics classes alone will miss most of the corpus.
The dataset covers 11,824 published records filed or published between 2015 and mid-2026, drawn from applicants ranging from research universities and hospital systems to instrument makers and pharmaceutical filers. Publication lags filing by roughly 18 months, so the final one to two years in any trend chart understate real activity.
Filing trend and technology composition
Two views of the same 11,824-record corpus: how filing volume has moved year over year, and how records distribute across IPC subclasses.
Filing trend, 2017–2026
Filings peaked in 2018 at 648 records, held near that level through 2021 (631), then declined to 314 by 2024 — a -50% move over that three-year span. 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a continued decline.
IPC subclass composition
A61K and G01N each appear in roughly 30% of the 11,824 records, ahead of G02B optical systems (17.3%) and A61B diagnosis/surgery (16.0%). Because records carry multiple classes, these shares sum to well over 100% and should be read individually against the full record count, not against each other as parts of a whole.
Shares are the percentage of the 11,824 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Confocal and Multiphoton Microscopy with Eureka
This page is one run against one query. Ask Eureka your own question about confocal and multiphoton microscopy and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a recent representative filing
Confocal microscopy apparatus and method for imaging a sample by chromatic confocal microscopy
A confocal microscopy apparatus for imaging a sample under investigation by chromatic confocal microscopy comprises an illumination source device arranged for creating illumination light having an illumination spectrum covering a plurality of illumination wavelengths, and a focusing device including at least one focusing lens configured for focusing the illumination light along an imaging axis into a plurality of wavelength-dependent focal planes across an axial imaging range, the same lens also collecting scattering light returned from the sample.Filed by Max Planck Society, published 2024-11-14 — illustrates the current generation of chromatic confocal designs built around a single shared focusing lens for both illumination and collection.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5837832A | Arrays of nucleic acid probes on biological chips | 2,192 |
| 2 | US7315019B2 | Arrays of optical confinements and uses thereof | 2,116 |
| 3 | US6485413B1 | Methods and apparatus for forward-directed optical scanning instruments | 1,840 |
| 4 | WO1995011995A1 | Arrays of nucleic acid probes on biological chips | 1,277 |
| 5 | US20160270656A1 | Methods and systems for diagnosing and treating health ailments | 1,199 |
| 6 | US7302146B2 | Apparatus and method for analysis of molecules | 690 |
| 7 | US7476503B2 | Apparatus and method for performing nucleic acid analysis | 595 |
| 8 | US5785651A | Distance measuring confocal microscope | 532 |
| 9 | US6002480A | Depth-resolved spectroscopic optical coherence tomography | 507 |
| 10 | US6248988B1 | Conventional and confocal multi-spot scanning optical microscope | 476 |
Citation counts favour older records simply because they have had more time to accumulate citations within the searched corpus — treat this table as a map of influence, not of current technical relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data tells a filer
Three patterns stand out once volume, composition and citation data are read together.
No single assignee dominates
The leader holds 485 records and the fifth-ranked assignee 161, but the top 5 together still account for only 13.2% of all records in scope. Compare that to the top 10 at 19.1% — the increment from rank 6 to 10 adds barely 6 points, meaning the long tail beyond the leaders is doing most of the filing.
Volume has pulled back from its peak
Filings ran at 631 in 2021 and fell to 314 by 2024, the last year that can be treated as complete given publication lag. Several of the largest historical filers show sharp year-over-year declines in the most recent complete year, consistent with a cooling rather than a still-rising field.
Therapeutic framing outweighs pure optics
Medicinal preparations (A61K) and material analysis (G01N) each sit near 30% of the corpus, ahead of optical elements (G02B) at 17.3%. Most patenting activity frames confocal and multiphoton imaging as a step inside a diagnostic or drug-development workflow rather than as instrument innovation on its own.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to confocal and multiphoton microscopy, with the prior art for and against each one.
Assignee landscape
University and hospital-affiliated research bodies dominate the ranked leaders, with instrument makers and one XR-hardware filer also present. Recent-year momentum has turned negative for most of the largest historical filers.
Research institutions lead by volume
The top-ranked assignee holds 485 records, well ahead of the field, but its recent-year filing has slowed sharply along with several other long-standing leaders.
Cross-institution filing is common among academic leaders
The strongest co-assignee pair in the dataset appears 116 times, reflecting joint research programmes between a university and an affiliated hospital, one of ten identified co-assignee relationships.
Several top-ranked filers pulled back sharply
More than one of the historically largest assignees dropped to a single record in the latest year, down 80–100% year over year. This pattern is broad enough across the leaders that it looks structural rather than specific to one filer's strategy.
| Assignee | Recent year | YoY |
|---|---|---|
| Max Planck Society | 2 | -33% |
| Massachusetts Institute of Technology | 1 | -83% |
| The General Hospital Corporation | 1 | -83% |
| Board of Regents, The University of Texas System | 1 | -80% |
| The Regents of the University of California | 0 | -100% |
| President and Fellows of Harvard College | 0 | -100% |
| The Board of Trustees of the Leland Stanford Junior University | 0 | -100% |
| Magic Leap, Inc. | 0 | -100% |
Where to take this analysis
The landscape points to a field with clear leaders but real room beyond them, and a technology mix that rewards looking past pure-optics classes.
Run a freedom-to-operate check across all relevant classes
Because most confocal and multiphoton filings sit in A61K, G01N or C12N rather than G02B alone, an FTO search limited to optical-instrument classes will miss the majority of relevant prior art.
Explore the full dataset in EurekaWatch the momentum shift, not just the leaderboard
Several of the largest historical assignees show sharp year-over-year declines in their most recent complete filing year — worth tracking before assuming past leaders will keep filing at past rates.
Track assignee momentum in EurekaCommon questions about this landscape
The ranked leader in this dataset holds 485 records, with the fifth-placed assignee at 161 and the tenth at 124. However, the top 5 assignees combined account for only 13.2% of the 11,824 records in scope, so leadership by volume does not translate into control of the field. Most of the filing activity sits in a long tail of research institutions and companies outside the ranked leaders.
Filing peaked in 2018 at 648 records and has since declined, falling from 631 in 2021 to 314 in 2024, a -50% move over that three-year span. 2024 is the last year in this dataset that can be treated as complete, because publication typically lags filing by around 18 months. The apparent drop in 2025 and 2026 reflects that lag rather than a confirmed slowdown, so it should not yet be read as the field's direction.
In this dataset, A61K (medicinal preparations) and G01N (material analysis and testing) each cover close to 30% of the 11,824 records, ahead of G02B (optical elements and systems) at 17.3%. That reflects how the technology is actually used: most patent claims bundle the imaging method with a diagnostic assay, a drug-screening application, or a genetic-engineering workflow rather than claiming the microscope hardware alone. A search or landscape limited to optics classes will therefore miss most of the relevant filings.
That filing, from Max Planck Society and published in November 2024, claims a chromatic confocal apparatus in which a single focusing lens both projects wavelength-dependent focal planes into the sample and collects the returned scattering light. Anyone designing a chromatic confocal instrument around a shared illumination-and-collection lens architecture should review this claim scope closely before finalising an optical path. It represents current-generation thinking in the field, so it is a useful reference point even for designs that diverge from it.
Relative to the dense core classes covering diagnostics, therapeutics and general optical elements, narrower operational parameters such as adaptive pinhole sizing tied to penetration depth, real-time laser power control for live-cell viability, and multiplexed spectral detection beyond simple dual-channel setups show comparatively thinner filing density. These are not guaranteed to be open, but they sit outside the heavily claimed core and are worth a focused prior-art check before committing R&D resources. Scanning-speed compensation for in vivo motion artefacts is another area with less apparent claim density than the core diagnostic classes.
Research Confocal and Multiphoton Microscopy in depth with Eureka
Go past this page: query the whole confocal and multiphoton microscopy corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.